A Phase 1 interventional study of aprepitant 165 mg and Comparator: aprepitant 185 mg in Chemotherapy-Induced Nausea and Vomiting, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-01-28.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing fosaprepitant in Vomiting — 2 open to participants now, 2 under way, 1 of them phase 3. fosaprepitant · Vomiting.
Among the 26 studies testing fosaprepitant in Vomiting, this one is the 20th largest by enrollment, is one of 3 that started in 2009, is one of 4 in phase 1, and was the 6th registered.
794 studies on the registry are indexed under Vomiting; 99 are open to participants now.
Browse Vomiting studies →2 of the 26 studies testing fosaprepitant in Vomiting are open now, in 1 country. Recruiting first, the newest first:
Montefiore Medical Center · Sites in United States
Ages 18+
Montefiore Medical Center · Sites in United States
Ages 18+
By country, each count listing its studies:
fosaprepitant: first FDA approval 2008 (EMEND), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 56 Vomiting studies recruiting now, 26 (46%) set no upper age limit and 24 (43%) stop at 75 or younger; 10 take children under 18; 17 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 8 · Phase 4 3
First in 2005; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is below the median of 103 across 673 interventional studies indexed under Vomiting.
Median enrollment 114 across the 26 interventional studies. Of the 21 that completed or were terminated, 18 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 26 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
29 studies in Vomiting by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 29 finished, 20 (69%) have results posted.
Among the 29 studies in Vomiting by Merck & Co., Inc, this one is the 26th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2009, is one of 6 in phase 1, and was the 15th registered.
Merck & Co., Inc’s Vomiting studies by the year they started, since 2002.
2 of the studies testing fosaprepitant in Vomiting that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06382012Phase 3Montefiore Medical CenterAntiemetic Fosaprepitant To Remedy Nausea and Vomiting | 2027-03 |
| NCT06740812Montefiore Medical CenterBroadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 26 studies testing fosaprepitant in Vomiting, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 29 in Vomiting:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess the bioequivalence of single oral doses of aprepitant (MK0869) to a single intravenous infusion of fosaprepitant (MK0517) and also determine the effect of food on the bioavailability of oral aprepitant.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
aprepitant 165 mg
Drug: aprepitant 165 mg
aprepitant 185 mg
Drug: Comparator: aprepitant 185 mg
fosaprepitant 150 mg
Drug: Comparator: fosaprepitant 150 mg
aprepitant with food
Drug: Comparator: aprepitant with food
Single dose of aprepitant 165 mg tablet in the fasted state during treatment period 1,2, or 3.
Single dose of aprepitant 185 mg tablet in the fasted state during treatment period 1, 2, or 3.
Single dose of fosaprepitant 150 mg intravenous infusion in the fasted state during treatment period 1,2, or 3.
Drug page: Aprepitant
Single dose of aprepitant 165 mg or 185 mg tablet in the fed state during treatment period 4.
Area Under the Curve (AUC(0 to Infinity)) Following Single Dose Administration of Aprepitant 165 mg or 185 mg and Fosaprepitant 150 mg
Time frame: Through 72 Hours Postdose
Peak Plasma Concentration (Cmax) Following Single Dose Administration of Aprepitant 165 mg or 185 mg and Fosaprepitant 150 mg.
Time frame: Through 72 Hours Postdose
| Milestone | A/B/C/D | B/C/A/D | C/A/B/D | A/C/B/E | B/A/C/E | C/B/A/E |
|---|---|---|---|---|---|---|
| Started | 7 | 7 | 7 | 7 | 7 | 7 |
| Completed | 7 | 7 | 7 | 7 | 6 | 7 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 |
| Milestone | A/B/C/D | B/C/A/D | C/A/B/D | A/C/B/E | B/A/C/E | C/B/A/E |
|---|---|---|---|---|---|---|
| Started | 7 | 7 | 7 | 7 | 6 | 7 |
| Completed | 7 | 7 | 7 | 7 | 6 | 7 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | A/B/C/D | B/C/A/D | C/A/B/D | A/C/B/E | B/A/C/E | C/B/A/E |
|---|---|---|---|---|---|---|
| Started | 7 | 7 | 7 | 7 | 6 | 7 |
| Completed | 7 | 7 | 7 | 7 | 6 | 7 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | A/B/C/D | B/C/A/D | C/A/B/D | A/C/B/E | B/A/C/E | C/B/A/E |
|---|---|---|---|---|---|---|
| Started | 7 | 7 | 7 | 7 | 6 | 7 |
| Completed | 7 | 7 | 7 | 7 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 |
| ng•hr/mL | 165 mg Aprepitant (Fasted State) | 185 mg Aprepitant (Fasted State) | 150 mg Fosaprepitant Dimeglumine (Fasted State) | 165 mg Aprepitant (Light) | 165 mg Aprepitant (High-Fat) | 185 mg Aprepitant (Light) | 185 mg Aprepitant (High-Fat) |
|---|---|---|---|---|---|---|---|
| Area Under the Curve (AUC(0 to Infinity)) Following Single Dose Administration of Aprepitant 165 mg or 185 mg and Fosaprepitant 150 mg | 34589 ± 39.7 | 39053 ± 37.5 | 37375 ± 39.5 | 37795 ± 48.4 | 50172 ± 22.0 | 51146 ± 27.2 | 60578 ± 57.5 |
| ng/mL | 165 mg Aprepitant (Fasted State) | 185 mg Aprepitant (Fasted State) | 165 mg Aprepitant (Light) | 165 mg Aprepitant (High-Fat) | 185 mg Aprepitant (Light) | 185 mg Aprepitant (High-Fat) |
|---|---|---|---|---|---|---|
| Peak Plasma Concentration (Cmax) Following Single Dose Administration of Aprepitant 165 mg or 185 mg and Fosaprepitant 150 mg. | 1738 ± 30.8 | 1636 ± 31.2 | 1870 ± 33.3 | 2362 ± 38.5 | 2116 ± 14.8 | 1995 ± 35.2 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 165 mg Aprepitant | — | 0/41 (0%) | 12/41 (29.3%) |
| 185 mg Aprepitant | — | 1/42 (2.4%) | 13/42 (31%) |
| 150 mg Fosaprepitant Dimeglumine | — | 0/41 (0%) | 15/41 (36.6%) |
| 165 mg Aprepitant (Fed State) | — | 0/21 (0%) | 6/21 (28.6%) |
| 185 mg Aprepitant (Fed State) | — | 0/20 (0%) | 3/20 (15%) |
| Event | 165 mg Aprepitant | 185 mg Aprepitant | 150 mg Fosaprepitant Dimeglumine | 165 mg Aprepitant (Fed State) | 185 mg Aprepitant (Fed State) |
|---|---|---|---|---|---|
| Accidental OverdoseInjury, poisoning and procedural complications | 0/41 | 1/42 | 0/41 | 0/21 | 0/20 |
| Event | 165 mg Aprepitant | 185 mg Aprepitant | 150 mg Fosaprepitant Dimeglumine | 165 mg Aprepitant (Fed State) | 185 mg Aprepitant (Fed State) |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 9/41 | 6/42 | 6/41 | 1/21 | 1/20 |
| SomnolenceNervous system disorders | 0/41 | 0/42 | 0/41 | 2/21 | 1/20 |
| DizzinessNervous system disorders | 3/41 | 3/42 | 1/41 | 0/21 | 0/20 |
| Oropharyngial PainRespiratory, thoracic and mediastinal disorders | 0/41 | 0/42 | 1/41 | 0/21 | 1/20 |
| Infusion Site IndurationGeneral disorders | 0/41 | 1/42 | 2/41 | 0/21 | 0/20 |
| Nasal CongestionRespiratory, thoracic and mediastinal disorders | 2/41 | 0/42 | 2/41 | 0/21 | 0/20 |
| Abdominal Pain UpperGastrointestinal disorders | 0/41 | 1/42 | 0/41 | 1/21 | 0/20 |
| DiarrhoeaGastrointestinal disorders | 0/41 | 0/42 | 0/41 | 1/21 | 0/20 |
| Chest PainGeneral disorders | 0/41 | 0/42 | 0/41 | 1/21 | 0/20 |
| Infusion Site MassGeneral disorders | 0/41 | 0/42 | 0/41 | 1/21 | 0/20 |
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 27.8 (18 to 43) |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 10 |
| Male | 32 |
| Height(Centimeters) | All Participants |
|---|---|
| Mean | 172.9 (151.1 to 190.5) |
| Weight(Kilograms) | All Participants |
|---|---|
| Mean | 74.2 (44.9 to 91.2) |
No study locations are listed for this record.
The record gives a start of Feb 2009, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2010, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fosaprepitant · Aprepitant